THE GALIEN FOUNDATION EXECUTIVE ADVISORY BOARD

Bruno COHEN (Chairman of the Board) LinkedIn

Bruno's expertise exclusively concerns moderating and stimulating communities within the field of Life Sciences. Graduate of the Superior Business School of Paris. Chevalier de la Legion d'Honneur.

Gil BASHE LinkedIn

Gil Bashe is executive vice president at Makovsky + Company, one of the nation's leading communications consulting firms and serves as one of the pharma industry's key communications counselors. Before joining Makovsky, served as chief executive of Health Quest Global Communication Partners, funded by GTCR Golder Rauner, one of the national largest private-equity firms, managing $4.5 billion in active assets. A Formerly Group Company CEO, CommonHealth, a WPP Group company, and Executive Vice President, Worldwide Health Practice Director, Hill and Knowlton (WPP Group).

Lee A. DAVIES LinkedIn

Lee A. Davies is Group Vice President, Health Practice, Makovsky, one of the nation’s leading independent communications consulting firms. With more than 35 years in health marketing communications, Lee has held leadership positions within the pharma sector and public relations industry. Before joining Makovsky, Lee was Director, Global Media Relations and Product Communications at Merck & Co. Inc., representing the company as spokesperson in cardiovascular, oncology, diabetes and women’s health. At Schering-Plough, Lee led global communications for all cardiovascular products. Earlier, he founded his own well-known medical education and healthcare public relations firm Davies and Murray.

Cynthia EKBERG TSAI

Cynthia Ekberg Tsai currently serves as Chairman and CEO of Viropro. Cynthia spent sixteen years on Wall Street and has been General Partner of several Venture Funds focused on technology transfer. Tsai lives in Washington, DC and Montana!

Les FUNTLEYDER LinkedIn

Les Funtleyder is responsible for the development and management of investment funds and related products. Les has been involved with the health care industry since 1993, both as a portfolio manager and analyst, and as an employee of major pharmaceutical companies.
His direct industry experience includes the direction of clinical and business research at Innovative Health Solutions, Les wrote Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services (McGraw Hill),. He is widely quoted in the Wall Street Journal, the New York Times, and the Financial Times, and is a frequent guest on CNBC, Bloomberg and NPR for his unique perspective on the healthcare sector and its constituent companies.
Les holds a Master of Public Heath (MPH) from Columbia University and a BA from Tulane University.

Shari GERSTEN LinkedIn

As an appointee of the Clinton Administration in the US Department of Commerce, Shari implemented the emerging markets strategy through high level forums and international trade missions along with outreach with senior leadership of US corporations, Shari's experience includes several years of leading international business development for a high tech business in Silicon Valley negotiating multi-million dollar strategic relationships. Shari is a cum laude graduate of Brandeis University and holds a law degree from American University, where she was a member of its Law Review.

Mark GOLDSTONE LinkedIn

Mark Goldstone is the current President of DDB Health Worldwide, Healthcare branch of Omnicom worldwide leader communication group. Mark holds a BSc (Hons) in Pharmacy. He is a member of the Institute of Practitioners in Advertising, the Marketing Society of Great Britain, and the Royal Pharmaceutical Society of Great Britain and was Chairman of the Pharmaceutical Communications Group.

Kimberly HA LinkedIn

Kimberly is an award-winning biopharmaceutical industry journalist and global editor of Biopharm Insight, a Financial Times Group product. She launched BioPharm Insight's global investigative reporting team in 2007. She began her career as a financial journalist in Hong Kong specializing in healthcare M&A, and previously was the lead sector specialist at Mergermarket, a division of the Financial Times Group.
She is a sought-after panelist and moderator at major healthcare investor conferences and events, including the Prix Galien Awards. In 2011, based on her extensive coverage of Alzheimer's disease, she was nominated by the Alzheimer's Association and was ultimately selected to be a National Press Foundation Fellow. Kimberly also is a recipient of the 2012 National Press Foundation and UN Foundation Global Vaccines Press Fellowship. In 2012, she was awarded the Association of Health Care Journalists Fellowship Award, which was supported by the New York State Health Foundation as well as the National Press Foundation Cancer Issues Fellowship.

William LOONEY LinkedIn

Bill Looney is editor of Pharmaceutical Executive magazine, which covers the science and the business of the industry. He has received numerous awards for reporting and editorial commentary; prior to his current role he was responsible for international policy initiatives as an executive with Pfizer.

John G. MOHR (Board Member) LinkedIn

CPA, CLP, (CONSULTS LLC)John is a multi-dimensional drug industry executive with expertise in managing emerging company issues. His distinguished career includes management of multi-million dollar brands and building products from clinic-to-market. His experience includes 12 years at Merck where he lead Financial Services for Merck's North America Operations followed by six years of responsibility in Marketing & New Product Planning for CNS and GI Products, including worldwide marketing franchise head for the blockbuster brand - Pepcid®. He was President of Fournier Pharma (US) where he built a strategic cardiovascular partnership with Abbott for TriCor, now a $1.5 billion brand. Most recently he led Corporate Development at CV Therapeutics leading to a major agreement with Menarini and managing the $1.4 billion M&A transaction with Gilead. John possesses a portfolio of worldwide contacts and provides is currently a independent consultant providing emerging companies with expertise in closing successful licensing and M&A transactions.

Chris O'TOOLE LinkedIn

Christopher O'Toole is a healthcare business professional with experience in pharma sales and marketing, in medical communications, and investment & virtual drug development. He is a co-founder and US Head of Nine-TZ Healthcare Ventures, a business consultancy providing commercial advisory and implementation for pharmaceutical and biotech companies.

Peter PITTS LinkedIn

Peter Pitts is President of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service, Peter served as FDA’s Associate Commissioner for External Relations, serving as senior communications and policy adviser to the Commissioner. In 2010, he was named by Modern Healthcare magazine as one of the 300 “most powerful people in American healthcare. Specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, DTC/ItP, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, nutritional labeling. He has served as an adjunct professor at Indiana University’s School of Public and Environmental Affairs and Butler University.

Barbara RYAN LinkedIn

Barbara Ryan is a managing director in the FTI Consulting Strategic Communications Consulting practice.
Ms. Ryan has more than 31 years of Wall Street experience as a sell-side research analyst covering the biopharmaceutical sector and providing financial analysis and industry expertise to institutional clients. Ms. Ryan's opinions and expertise are widely sought; she is frequently quoted in the press and is a Guest Contributor for CNBC.
For 19 years prior to joining FTI Consulting, Ms. Ryan was a Managing Director at Deutsche Bank and Head of the company's Pharmaceutical Research Team. She is widely recognized as an authority on the trends and outlook for the global pharmaceutical industry and has been publishing her analysis throughout her career. Ms. Ryan also served as the lead analyst on several high profile IPOs such as Express Scripts, PSSI, Flamel Technologies, and Henry Schein.
Ms. Ryan currently serves on Pharmaceutical Executive 's Editiorial Advisory Board, as well as the Healthcare Advisory Board of the Executive Council of New York. Ms. Ryan has been a guest lecturer at top university MBA programs including Columbia and University of California at Berkeley. Barbara is Chair of the Board of Villa Maria School for children with learning disabilities in Stamford, Ct.
Ms. Ryan received a B.S. in finance from the University of Massachusetts at Amherst.

Philippe SCHAISON (Board Member) LinkedIn

PharmD - MBA, President Clarins International - Global Skin Care Company. Philippe is a performance driven health and consumer leader with expertise in turnarounds, mergers & acquisitions and strategic implementation. He is a charismatic leader with extensive experience in leading global organizations with the ability to implement successful operations and drive profitability. Global President with multiple turn around successes who delivered significant top & bottom line growth while upgrading talent and reducing expenses. Philippe has significant experience in Asia, South America and Europe.

Zev S. SCHERL (Treasurer) LinkedIn

Zev Scherl is a General Partner with NewSpring Capital which has over $700 million of capital under management. More about his background can be found at http://www.newspringcapital.com/nsc_team.html#teamCHV

SEE ALSO